drugset
drugset / Trial / NCT02594332

Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study

NCT02594332 ↗

Phase 3 Terminated 29 enrolled Johannes Gutenberg University Mainz GlaxoSmithKline · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the MEMORY trial is to compare the effects of mepolizumab with Placebo on airway physiology in patients with eosinophilic asthma

Timeline

Start
2015-11-17
Primary completion
2017-05-22
Completion
2017-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Mepolizumab Monoclonal antibody 100 mg Subcutaneous

Indications

asthma